Osaic Holdings
KROS icon

Osaic Holdings’s Keros Therapeutics KROS Stock Holding History

Osaic Holdings’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22K Buy
2,053
+1
+0% +$11 ﹤0.01% 6100
2026
Q1 		$22.7K Sell
2,052
-344
-14% -$5.31K ﹤0.01% 5770
2025
Q4 		$48.8K Buy
2,396
+1,966
+457% +$34.5K ﹤0.01% 5249
2025
Q3 		$6.8K Buy
430
+356
+481% +$5.26K ﹤0.01% 6585
2025
Q2 		$988 Buy
+74
New +$999 ﹤0.01% 7148
2025
Q1 		– Sell
-20
Closed -$317 – 7593
2024
Q4 		$317 Sell
20
-147
-88% -$7.64K ﹤0.01% 7114
2024
Q3 		$9.7K Sell
167
-66
-28% -$3.26K ﹤0.01% 5834
2024
Q2 		$10.6K Sell
233
-66
-22% -$3.55K ﹤0.01% 5751
2024
Q1 		$19.8K Sell
299
-421
-58% -$25K ﹤0.01% 5375
2023
Q4 		$28.6K Sell
720
-164
-19% -$5.14K ﹤0.01% 5280
2023
Q3 		$28.2K Hold
884
– – ﹤0.01% 5366
2023
Q2 		$35.5K Buy
+884
New +$38.8K ﹤0.01% 5169

Other funds holding KROS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Osaic Holdings's KROS Position: Q2 2026 in Review

Osaic Holdings increased its Keros Therapeutics (KROS) stake by 0.05% in Q2 2026, buying an estimated $11 and bringing the position to 2,053 shares worth $22K. The position accounts for ﹤0.01% of the portfolio, ranked #6100.

Osaic Holdings first reported a position in KROS in Q2 2023 and has held it in 12 quarters since. The position peaked at $48.8K in Q4 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

  • Osaic Holdings held 2,053 shares of Keros Therapeutics worth $22K as of Q2 2026.
  • Osaic Holdings bought 1 Keros Therapeutics share in Q2 2026, an estimated $11.
  • Keros Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #6100 holding.
  • Osaic Holdings first reported a position in Keros Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Osaic Holdings's Keros Therapeutics position peaked at $48.8K in Q4 2025.
  • 132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.